S Asia | SE Asia | p value (adj) | OR | LCI | UCI | ||
---|---|---|---|---|---|---|---|
Species assignment | 102 | 100 | |||||
K. pneumoniae | 100 (98%) | 87 (87%) | 0.011 | 0.13 | 0.01 | 0.62 | * |
K. variicola | 1 (1%) | 4 (4%) | 0.838 | 4.18 | 0.40 | 209.04 | |
K. quasipneumoniae ssp. quasipneumoniae | 1 (1%) | 0 (0%) | na | na | na | na | |
K. quasipneumoniae ssp. similipneumoniae | 0 (0%) | 9 (9%) | na | na | na | na | |
Features of K. pneumoniae sensu stricto | |||||||
Sequence type assignment | 100 | 87 | |||||
ST15 | 11 (11%) | 15 (17%) | 1.158 | 1.68 | 0.67 | 4.32 | |
ST14 | 16 (16%) | 2 (2%) | 0.008 | 0.12 | 0.01 | 0.56 | ** |
ST23 | 2 (2%) | 12 (14%) | 0.015 | 7.76 | 1.65 | 73.39 | * |
ST231 | 17 (17%) | 0 (0%) | 5.14 × 10−5 | 0.00 | 0.0 | 0.24 | ** |
Capsular serotype prediction | 79 | 87 | |||||
KL1 | 2 (2.5%) | 13 (15%) | 0.012 | 6.70 | 1.44 | 63.22 | * |
KL2 | 4 (5.1%) | 11 (13%) | 0.216 | 2.70 | 0.76 | 12.15 | |
Antimicrobial resistance prediction | 100 | 87 | |||||
Multi-drug resistant (≥ 3 acquired classes) | 81 (81%) | 44 (51%) | 1.06 × 10−4 | 0.24 | 0.12 | 0.48 | ** |
Aminoglycosides | 76 (76%) | 41 (47%) | 0.001 | 0.28 | 0.14 | 0.55 | ** |
Fluoroquinolones | 80 (80%) | 39 (45%) | 7.13 × 10−6 | 0.21 | 0.10 | 0.41 | ** |
Phenicols | 27 (27%) | 25 (29%) | 7.833 | 1.09 | 0.55 | 2.17 | |
Sulfonamides | 63 (63%) | 42 (48%) | 0.493 | 0.55 | 0.29 | 1.02 | |
Tetracyclines | 24 (24%) | 39 (45%) | 0.029 | 2.56 | 1.32 | 5.05 | * |
Trimethoprim | 62 (62%) | 38 (44%) | 0.118 | 0.48 | 0.25 | 0.89 | |
3rd-generation cephalosporins (ESBL) | 60 (60%) | 41 (47%) | 0.949 | 0.60 | 0.32 | 1.11 | |
Carbapenems | 47 (47%) | 1 (1%) | 7.13 × 10−13 | 0.01 | 0.0 | 0.08 | ** |
Virulence prediction | 100 | 87 | |||||
Yersiniabactin (ybt) | 65 (65%) | 46 (53%) | 0.205 | 0.61 | 0.32 | 1.13 | |
Aerobactin (iuc) | 27 (27%) | 32 (37%) | 0.319 | 1.57 | 0.81 | 3.07 | |
Iuc lineages | 100 | 87 | |||||
iuc 1 | 13 (13%) | 27 (31%) | 0.012 | 2.99 | 1.36 | 6.86 | * |
iuc 3 | 0 (0%) | 5 (6%) | 0.061 | na | 1.08 | inf | |
iuc 5 | 12 (12%) | 0 (0%) | 0.001 | 0.00 | 0.0 | 0.8 | ** |
AMR and virulence convergence | 100 | 87 | |||||
ESBL and ybt | 45 (45%) | 26 (30%) | 0.144 | 0.52 | 0.27 | 0.99 | |
ESBL and iuc | 16 (16%) | 1 (1%) | 0.001 | 0.06 | 0.0 | 0.41 | ** |
CP and ybt | 37 (37%) | 1 (1%) | 1.79 × 10− 10 | 0.02 | 0.0 | 0.13 | ** |
CP and iuc | 13 (13%) | 0 (0%) | na | na | 0.0 | 0.34 |